Becton Dickinson & Company (BDX) Company Profile

Becton Dickinson & Company (BDX) is a global medical technology firm that manufactures and sells a vast array of medical devices, instruments, and diagnostic systems. Its products, such as syringes, needles, IV catheters, and diagnostic analyzers, are used in hospitals, laboratories, and clinics worldwide. Its customers are primarily healthcare institutions, making its revenue stream essential and relatively stable. Applying the GoodMoat framework, BDX scores well on several moat criteria: it benefits from high switching costs as its devices are integrated into clinical workflows, possesses regulatory barriers due to stringent FDA approvals, and has significant scale and brand recognition in its niche markets. However, its growth profile is a key concern. With revenue growth of just 1.6% YoY, it fails to meet the framework's standard for durable, double-digit growth. Key red flags to watch include its elevated valuation, with a P/E of 25.7x despite modest growth, and potential margin compression risks in a competitive environment, though its current operating margin of 11.8% is stable. A value investor might be interested in its defensive business model, strong free cash flow yield of 5.9%, and dividend. Yet, the combination of low growth, a full valuation near the GoodMoat target of $146.37, and an ROE of 6.9% that is below the framework's high-return threshold suggests the opportunity is not clearly favourable without a more attractive price. Analysis based on data as of 2024-05-15.